Core Viewpoint - NEXGEL, Inc. has announced a definitive agreement for the issuance and sale of 413,044 shares of common stock at $2.30 per share, along with unregistered warrants for an additional 206,522 shares at an exercise price of $4.25, aimed at strengthening its balance sheet and providing working capital for anticipated growth in the second half of the year [1][2]. Group 1: Financial Details - The total number of shares being offered is 413,044 at a price of $2.30 each [1]. - Concurrently, NEXGEL will issue unregistered warrants to purchase up to 206,522 shares at an exercise price of $4.25, which are immediately exercisable for five years [1][2]. - The financing, combined with a recent $1 million non-dilutive advance from STADA, enhances the company's cash position [2]. Group 2: Regulatory Information - The shares are being offered under the company's shelf registration statement on Form S-3, which was declared effective by the SEC on June 7, 2023 [3]. - The unregistered warrants are offered under an exemption from registration requirements of the Securities Act [4]. Group 3: Company Overview - NEXGEL is a provider of healthcare, beauty, and OTC products, specializing in ultra-gentle, high-water-content hydrogels [6]. - The company has over two decades of experience in developing and manufacturing electron-beam, cross-linked hydrogels [6].

Core Viewpoint - Erayak Power Solution Group Inc. has entered into a securities purchase agreement for the sale of 107,692,307 shares at a price of $0.065 per share, aiming to raise approximately $7 million in gross proceeds [1][2]. Group 1: Offering Details - The offering involves the purchase and sale of Class A ordinary shares or pre-funded warrants, with a purchase price of $0.065 per share [1]. - The transaction is expected to close on or about August 1, 2025, pending customary closing conditions [2]. - Craft Capital Management is acting as the sole placement agent for this offering [2]. Group 2: Regulatory Information - The offering is conducted under a shelf registration statement on Form F-3, which was declared effective by the SEC on May 16, 2024 [3]. - A prospectus supplement detailing the terms of the offering will be filed with the SEC prior to closing [4]. Group 3: Company Overview - Erayak specializes in manufacturing, research and development, and wholesale and retail of power solution products, including inverters, generators, and smart chargers [6]. - The company's products are primarily used in agricultural and industrial vehicles, recreational vehicles, and outdoor living products [6].

Core Viewpoint - Garden Stage Limited has entered into a definitive agreement for a registered direct offering of 38,406,345 ordinary shares at a price of $0.11 per share, expected to raise approximately $4.2 million in gross proceeds [1][2]. Group 1: Offering Details - The offering includes the option for pre-funded warrants at the same price, with an exercise price of $0.001 per share [1]. - The transaction is anticipated to close on or about July 25, 2025, pending customary closing conditions [2]. - The offering is conducted under a shelf registration statement previously filed and declared effective by the SEC [3]. Group 2: Company Overview - Garden Stage Limited is a Hong Kong-based financial services provider engaged in placing and underwriting services, securities dealing and brokerage, asset management, and investment advisory services [5]. - The company operates through wholly-owned subsidiaries, including I Win Securities Limited and I Win Asset Management Limited, both licensed for various regulated activities under Hong Kong's SFO [5].

Group 1 - Safety Shot, Inc. announced a registered direct offering of 28,648,648 shares of common stock at a price of $0.37 per share, raising approximately $10.6 million in gross proceeds [1][2]. - In a concurrent private placement, the company issued warrants to purchase up to 57,297,296 shares of common stock, with an exercise price of $0.37 per share, exercisable immediately and expiring in five years [2]. - The closing of the offering is expected to occur on or about July 22, 2025 [3]. Group 2 - The shares are being offered under a shelf registration statement filed with the SEC, which was declared effective on November 1, 2024 [4]. - The CEO of Safety Shot emphasized that this financing is crucial for strengthening the balance sheet and supporting expanded operations following the recent merger approval with Yerbaé [5]. - Dominari Securities, LLC acted as the exclusive placement agent for the offering [5]. Group 3 - Safety Shot, Inc. is known for its patented wellness product, Sure Shot, which lowers blood alcohol content while enhancing clarity, energy, and mood [7].

Core Viewpoint - Draganfly Inc. has entered into a securities purchase agreement to raise approximately US$25 million through the sale of 4,672,895 units at a price of US$5.35 per unit [1][3]. Group 1: Offering Details - Each unit consists of one common share and one common share purchase warrant, with the warrants exercisable at CA$7.3579 per share for five years [2]. - The offering is expected to close around July 21, 2025, pending customary closing conditions [3][4]. - The offering is made under an effective shelf registration statement and a Canadian short form base shelf prospectus [5]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including funding new product capabilities, working capital, and potential acquisitions [3]. Group 3: Company Background - Draganfly Inc. is a pioneer in drone solutions, AI-driven software, and robotics, with over 25 years of innovation in various sectors including public safety and agriculture [8].

Core Viewpoint - Bit Digital, Inc. has announced a registered direct offering of 22 million ordinary shares at a price of $3.06 per share, aiming to raise approximately $67.3 million in gross proceeds before fees and expenses [1][2]. Group 1: Offering Details - The offering is expected to close around July 15, 2025, pending customary closing conditions [1]. - The net proceeds from the offering will be utilized to purchase Ethereum [2]. - B. Riley Securities is acting as the exclusive Placement Agent for this offering [2]. Group 2: Regulatory Information - The securities are being offered under a shelf registration statement on Form S-3, which was filed with the SEC on April 30, 2025, and declared effective on June 20, 2025 [3]. - A preliminary prospectus supplement has been filed with the SEC, and a final prospectus supplement will also be filed and made available on the SEC's website [3]. Group 3: Company Overview - Bit Digital is a publicly traded digital asset platform focused on Ethereum-native treasury and staking strategies, having begun to accumulate and stake ETH in 2022 [5]. - The company operates one of the largest institutional Ethereum staking infrastructures globally, offering advanced validator operations and institutional-grade custody [5]. - Bit Digital aims to provide secure, scalable, and compliant access to on-chain yield through strategic partnerships within the Ethereum ecosystem [5].

Core Viewpoint - SeaStar Medical Holding Corporation has announced a definitive agreement for the issuance and sale of 5,242,464 shares of common stock at a price of $0.763 per share, along with unregistered warrants to purchase an equal number of shares at an exercise price of $0.638, aiming to raise approximately $4 million for general corporate purposes [1][2]. Group 1: Offering Details - The offering includes a registered direct offering priced at-the-market under Nasdaq rules and a concurrent private placement for unregistered warrants [1][2]. - The gross proceeds from the offering are expected to be around $4 million, with net proceeds intended for general corporate purposes, including working capital and capital expenditures [2]. Group 2: Regulatory and Compliance Information - The shares are being offered under a shelf registration statement previously filed with the SEC, which became effective on December 22, 2023 [3]. - The unregistered warrants are not registered under the Securities Act and cannot be sold in the U.S. without an effective registration statement or applicable exemption [4]. Group 3: Company Overview - SeaStar Medical is focused on transforming treatments for critically ill patients facing organ failure, with its first product, QUELIMMUNE, approved by the FDA in 2024 for life-threatening acute kidney injury in pediatric patients [6]. - The company’s Selective Cytopheretic Device therapy has received Breakthrough Device Designation for six therapeutic indications, indicating a potential for expedited approval processes [6]. - SeaStar is conducting a pivotal trial of its SCD therapy in adult patients with acute kidney injury, a condition affecting over 200,000 adults in the U.S. annually [6].

Core Viewpoint - Cyngn Inc. has announced a registered direct offering with a single institutional investor, raising approximately $17.2 million through the sale of shares and pre-funded warrants at a price of $7.50 per share [1][3]. Group 1: Offering Details - The offering includes the sale of 2,293,333 shares of Common Stock or Pre-Funded Warrants, with the public offering price set at $7.50 per share [2]. - Pre-Funded Warrants are immediately exercisable and can be exercised at any time until fully exercised, with a minimal exercise price of $0.00001 [2]. - The transaction is expected to close around June 30, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for general corporate purposes and working capital [3]. Group 3: Legal and Regulatory Information - Aegis Capital Corp. is the exclusive placement agent for the offering, while Sichenzia Ross Ference Carmel LLP and Kaufman & Canoles, P.C. are acting as legal counsel for the company and the placement agent, respectively [4]. Group 4: Company Overview - Cyngn develops autonomous vehicle technology aimed at addressing challenges faced by industrial organizations, such as labor shortages and safety incidents [8]. - The company's DriveMod technology allows customers to integrate self-driving technology into their operations without significant upfront costs or infrastructure changes [9]. - DriveMod is currently available on specific models like Motrec MT-160 Tuggers and BYD Forklifts, with capabilities such as hauling up to 12,000 lbs and a payback period of less than 2 years [10].

Core Points - Houston American Energy Corp. has entered into a definitive agreement for the purchase and sale of 81,629 shares of common stock at a price of $14.80 per share in a registered direct offering [1] - The gross proceeds from this offering are expected to be approximately $1.2 million, with net proceeds of around $1 million intended for general corporate purposes [2] - The offering is being conducted under a shelf registration statement previously filed and declared effective by the SEC [3] - The company has appointed Univest Securities, LLC as the sole placement agent for the offering, entitled to an 8.0% fee on the proceeds [4]

Company Overview - Houston American Energy Corp. is an independent oil and gas company engaged in the acquisition, exploration, exploitation, development, and production of natural gas, crude oil, and condensate [7] - The company's principal properties are located primarily in the Texas Permian Basin, Colombia, and the onshore Louisiana Gulf Coast region [7] Offering Details - Houston American Energy Corp. has completed a registered direct offering, selling 223,762 shares of common stock at a purchase price of $10.60 per share, resulting in gross proceeds of approximately $2.37 million [2][3] - The net proceeds from the offering, estimated at approximately $2.1 million, are intended for general corporate purposes [3] Placement Agent - Univest Securities, LLC acted as the sole placement agent for the offering [3]